News

Roche: RoActemra beats Humira
Enlarge image

BusinessSwitzerland

Roche: RoActemra beats Humira

08.06.2012 - Roche's rheumatoid arthritis treatment RoActemra reduces symptoms more effectively than Abbott Laboratories' Humira when given as a single treatment.

Basel – As the Swiss company reported, a Phase IV trial showed that after 24 weeks of treatment 65% of patients who received RoActemra (tocilizumab) experienced a 20% reduction in swollen and tender joints compared with 49% of those on Humira (adalimumab). „As there are a number of therapies approved for patients with rheumatoid arthritis, it is important for them and their healthcare provider to have the information they need to choose the best individual treatment option,“ said Hal Barron, Chief Medical Officer and Head, Global Product Development. While Roche strongly advocates for its RoActemra, Analysts seem to be less convinced: „Despite these strong efficacy results, it is difficult to assess whether these trial results can be successfully exploited to bring about a change in physicians' prescription habits,“ said Vontobel analyst Andrew Weiss.

„Among a treatment environment of nine different medicines, it is very difficult to make an individual treatment decision for the physician“, acknowledged Karsten Jung, Head of GPS Immunology at Roche, adding that the study aimed at giving comparative data to doctors to help them to decidea in favor of RoActemra when prescribing a treatment.

FDA and EMA have approved RoActemra for use in patients who are either intolerant to or have failed to respond to other medicines to treat inflammation. Roche earned CHF184m in the first quarter 2012 (+46%). Analysts expect peak sales of up to US$2b for the drug. Rheumatoid arthritis and related diseases are one of the most lucrative areas for pharma companies, generating more than US$20b in annual sales. Humira sales are expected to reach US$8.7bn in 2012, according to an EvaluatePharma report.

http://www.european-biotechnology-news.com/news/news/2012-02/roche-roactemra-beats-humira.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.32 CHF14.29%
  • SANTHERA92.00 CHF5.75%
  • SARTORIUS106.00 EUR4.07%

FLOP

  • THERAMETRICS0.06 CHF-14.29%
  • EPIGENOMICS5.07 EUR-7.31%
  • 4SC0.85 EUR-6.59%

TOP

  • ADDEX3.56 CHF52.8%
  • CYTOS0.32 CHF45.5%
  • BB BIOTECH244.00 EUR23.3%

FLOP

  • ACTELION96.95 CHF-18.3%
  • THERAMETRICS0.06 CHF-14.3%
  • MAGFORCE4.65 EUR-13.2%

TOP

  • SANTHERA92.00 CHF2259.0%
  • BB BIOTECH244.00 EUR94.0%
  • CO.DON2.30 EUR60.8%

FLOP

  • CYTOS0.32 CHF-89.9%
  • MOLOGEN5.82 EUR-51.1%
  • 4SC0.85 EUR-50.3%

No liability assumed, Date: 25.01.2015